TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36124872

Group type: EXPERIMENTAL
Intervention: Timely reperfusion in patients with ST-elevation ACS
Number of subjects: 5107

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy at discharge
Number of subjects: 5107
Study: 36124924

Group type: EXPERIMENTAL
Intervention: Talazoparib 1 mg/day (0.75 mg/day for moderate renal impairment)
Number of subjects: 127
Study: 36125017

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol TCI anaesthesia during calibration phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOL index response to a tetanic stimulus under remifentanil antinociception
Number of subjects: 0
Study: 36125116

Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) used to control a virtual hand, specific details on dosage and duration not available.
Number of subjects: 1
Study: 36125208

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) chromatin binding features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic analyses of AR chromatin binding features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AR chromatin binding patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies on AR cistrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of therapeutic targets
Number of subjects: 0
Study: 36125263

Group type: EXPERIMENTAL
Intervention: Durvalumab + Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Durvalumab alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV+ samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathologic responders
Number of subjects: 0
Study: 36125279

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ubrogepant 25 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 36125352

Group type: EXPERIMENTAL
Intervention: Positive involvement behaviors during trauma narration
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Negative involvement behaviors during trauma narration
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Stronger alliance
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Trauma-related self-disclosure
Number of subjects: 65
Study: 36125356

Group type: EXPERIMENTAL
Intervention: Inflammatix Severity 2 classifier
Number of subjects: 397

Group type: COMPARATOR
Intervention: Lactate
Number of subjects: 397

Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 397

Group type: COMPARATOR
Intervention: qSOFA
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Combination of qSOFA and IMX-SEV-2
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: High-severity (rule-in) interpretation band of IMX-SEV-2
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Low-severity (rule-out) band of IMX-SEV-2
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: IMX-SEV-2
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Combination of IMX-SEV-2 and qSOFA
Number of subjects: 397
Study: 36125366

Group type: EXPERIMENTAL
Intervention: BA.2 breakthrough infection in triple-immunized individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BA.2 convalescent sera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omicron BA.1 convalescent sera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to Omicron BA.2
Number of subjects: 0
Study: 36125379

Group type: EXPERIMENTAL
Intervention: Low-field-strength MRI in children and adolescents with post-COVID-19 condition
Number of subjects: 54
Study: 36125855

Group type: EXPERIMENTAL
Intervention: Acceset digital peer support intervention (n=50 seekers, n=30 befrienders, n=30 moderators) for 3 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-listed control group (n=50)
Number of subjects: 100
Study: 36126069

Group type: EXPERIMENTAL
Intervention: Intraspinal pressure monitoring using a fiberoptic pressure monitor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Measurement of physiological parameters including spinal cord perfusion pressure, spinal cord blood volume, spinal cord compliance, and vascular reactivity indices
Number of subjects: 20
Study: 36126109

Group type: EXPERIMENTAL
Intervention: OCTA parameters in moderate-advanced glaucoma
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: OCTA parameters in early glaucoma
Number of subjects: 144
Study: 36126126

Group type: EXPERIMENTAL
Intervention: Myocardial T1 mapping
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Extracellular volume fraction (ECV) measurement
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Myocardial T2 mapping
Number of subjects: 1576
Study: 36126143

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation for AF in patients with HFpEF
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cryoballoon ablation for AF in patients without HFpEF
Number of subjects: 102
Study: 36126298

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill adherence
Number of subjects: 0
Study: 36126315

Group type: EXPERIMENTAL
Intervention: Compression therapy, details on dosage and duration not available.
Number of subjects: 0
Study: 36126902

Group type: COMPARATOR
Intervention: Synbiotics
Number of subjects: 250

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 250
Study: 36127090

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI combined with liquid biopsies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard clinico-pathological information
Number of subjects: 100
Study: 36127228

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 1076
Study: 36127539

Group type: EXPERIMENTAL
Intervention: Peer Specialists (PSs) integration in primary care settings
Number of subjects: 52

Group type: COMPARATOR
Intervention: External facilitation
Number of subjects: 52
Study: 36127713

Group type: EXPERIMENTAL
Intervention: e-EQ-5D-5L/VAS
Number of subjects: 665
Study: 36127767

Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg oral once daily (3-week cycle; 2 weeks on, 1 week off)
Number of subjects: 31
Study: 36127770

Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA) monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial dd-cfDNA determination
Number of subjects: 0
Study: 36127853

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (cALND) omission
Number of subjects: 1421

Group type: COMPARATOR
Intervention: Completion axillary lymph node dissection (cALND)
Number of subjects: 1421
Study: 36127922

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 126
Study: 36128334

Group type: EXPERIMENTAL
Intervention: Canakinumab plus standard-of-care
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo plus standard-of-care
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 36129032

Group type: EXPERIMENTAL
Intervention: Alteplase at 0.6 mg/kg
Number of subjects: 915

Group type: COMPARATOR
Intervention: No oral anticoagulants
Number of subjects: 915
Study: 36129046

Group type: EXPERIMENTAL
Intervention: Global Work Index (GWI) measurement in patients with elevated troponin (n=71)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: GWI measurement in relation to disease severity and all-cause death
Number of subjects: 305
Study: 36129052

Group type: EXPERIMENTAL
Intervention: Covered stent deployment
Number of subjects: 43343

Group type: EXPERIMENTAL
Intervention: Procedural major adverse cardiac events
Number of subjects: 43343
Study: 36129273

Group type: EXPERIMENTAL
Intervention: MMA embolization
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Factor Xa inhibitor use
Number of subjects: 322
Study: 36129459

Group type: EXPERIMENTAL
Intervention: VB10.16
Number of subjects: 34
Study: 36129471

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus eribulin
Number of subjects: 30
Study: 36129579

Group type: EXPERIMENTAL
Intervention: Early-follicular phase (EFP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Late-follicular phase (LFP)
Number of subjects: 21
Study: 36129681

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography monitoring indicators (including respiratory variability of inferior vena cava diameter, tricuspid annular plane systolic excursion)
Number of subjects: 150
Study: 36129688

Group type: EXPERIMENTAL
Intervention: Apremilast, 30 mg, twice daily
Number of subjects: 70
Study: 36129735

Group type: EXPERIMENTAL
Intervention: GCSWLI (gender- and culturally sensitive weight loss intervention) with mHealth support including tailored SMS, Fitbit Charge 2, and Fitbit Aria Smart Scale
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Use of Fitbit technology
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Use of smart scale
Number of subjects: 18
Study: 36129839

Group type: EXPERIMENTAL
Intervention: CHIP testing recommended after vignette presentation
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: CHIP testing preference after presenting CHIP-independent risks
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: CHIP testing preference after presenting CHIP-associated risks
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Preference for testing when offered a CHIP clinic
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Preference for testing when offered hypothetical CHIP treatment
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Desire for CHIP testing among participants
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Anxiety caused by learning about CHIP
Number of subjects: 528
Study: 36129967

Group type: EXPERIMENTAL
Intervention: NJH395 (Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate)
Number of subjects: 18
Study: 36130079

Group type: EXPERIMENTAL
Intervention: Occipital alpha relative power during eyes-closed states
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Occipital theta relative power during eyes-open states
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Frontal theta relative power during eyes-open states
Number of subjects: 26
Study: 36130086

Group type: EXPERIMENTAL
Intervention: Perception threshold tracking using electrical currents with different shapes, duration, and intensities applied by skin electrodes activating large and small fibers.
Number of subjects: 80
Study: 36130137

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study: 36130238

Group type: EXPERIMENTAL
Intervention: Portable hemoglobinometer (HemoCue 301)
Number of subjects: 896

Group type: COMPARATOR
Intervention: Automated hematology analyzers (AHA)
Number of subjects: 896
Study: 36130327

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 988
Study: 36130401

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Calprotectin
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: CRP and IL-6 combination
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: CRP and IL-6 optimal cutoff values
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: CRP and PCT
Number of subjects: 391
Study: 36130480

Group type: EXPERIMENTAL
Intervention: High-fructose diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-glucose diet
Number of subjects: 0
Study: 36130508

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched healthy donors
Number of subjects: 9
Study: 36130693

Group type: EXPERIMENTAL
Intervention: Radiotherapy with doses of 60 to 72 Gy in 2 Gy fractions
Number of subjects: 205
Study: 36130734

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Opioid antagonists
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Mood stabilisers
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 1193
Study: 36130741

Group type: EXPERIMENTAL
Intervention: Implementation of systematic testing at admission in the STEMI cohort
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Implementation of plan blanc concentrating resources in emergency activities in the STEMI cohort
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Per-wave period management times for stroke
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Per-wave period management times for STEMI
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Changes in use of care during per-wave period for STEMI
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Associations between reorganisations and stroke management times
Number of subjects: 9218
Study: 36130748

Group type: EXPERIMENTAL
Intervention: Stand-Alone Left Atrial Appendage Occlusion (LAAO)
Number of subjects: 0
Study: 36130762

Group type: EXPERIMENTAL
Intervention: Postoperative MRI or CT imaging (timing not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed postoperative imaging (between 36 and 72 hours postoperatively)
Number of subjects: 0
Study: 36131237

Group type: EXPERIMENTAL
Intervention: Language-supported group antenatal care (gANC)
Number of subjects: 44
Study: 36131333

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (ILS)
Number of subjects: 3147

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3147

Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 3147
Study: 36131349

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: General floor treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ICU treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Maximal exercise capacity
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary impairment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Post-COVID syndrome
Number of subjects: 71
Study: 36131848

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 14 days, limiting food and beverages to a 10-h window.
Number of subjects: 39
Study: 36131934

Group type: EXPERIMENTAL
Intervention: CAR-T-cell therapy
Number of subjects: 133
Study: 36133308

Group type: EXPERIMENTAL
Intervention: 1,5-Anhydroglucitol (1,5-AG) levels
Number of subjects: 2970
Study: 36133827

Group type: EXPERIMENTAL
Intervention: Prescription opioid misuse (POM)
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Overuse of opioids
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Use of opioids for effects other than analgesia
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Withdrawal syndrome
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Craving for opioids
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Factors associated with POM
Number of subjects: 951
Study: 36133956

Group type: EXPERIMENTAL
Intervention: Acute exercise (watt-max test and four high-intensity intervals)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 20
Study: 36134579

Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adeno-associated virus-mediated restoration of cardiac SIRT3 expression
Number of subjects: 3

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 3
Study: 36134657

Group type: EXPERIMENTAL
Intervention: 8-week supervised aerobic training intervention
Number of subjects: 21
Study: 36135045

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine (enrolled in NRDL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine (not enrolled in NRDL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 0
Study: 36135453

Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 160
Study: 36136180

Group type: EXPERIMENTAL
Intervention: Computer-guided buccal cortical plate separation
Number of subjects: 10
Study: 36136178

Group type: EXPERIMENTAL
Intervention: Short-type single-balloon enteroscopy (short SBE)
Number of subjects: 37
Study: 36136274

Group type: EXPERIMENTAL
Intervention: Lanreotide depot
Number of subjects: 99
Study: 36136294

Group type: EXPERIMENTAL
Intervention: Socazolimab (5 mg/kg)
Number of subjects: 104
Study: 36136377

Group type: EXPERIMENTAL
Intervention: Music Imagery (8-weekly, individual sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Music Listening (independent music listening)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 60
Study: 36136523

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (≤20 U/kg, max. 500 U per injection cycle for ≤6 injection cycles for spasticity; 20-75 U per injection cycle for ≤4 injection cycles for sialorrhea)
Number of subjects: 1159
Study: 36136794

Group type: EXPERIMENTAL
Intervention: Confidence in the therapist
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Confidence in the treatment
Number of subjects: 587
Study: 36136804

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact cognition (noMCI)
Number of subjects: 0
Study: 36136811

Group type: EXPERIMENTAL
Intervention: Detectable urine-TFV
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Undetectable urine-TFV
Number of subjects: 198
Study: 36136994

Group type: EXPERIMENTAL
Intervention: Cardiac surgeries associated with diabetes, smoking, and elderly age in winter
Number of subjects: 9838

Group type: EXPERIMENTAL
Intervention: Cardiac surgeries in elderly patients without diabetes and smoking
Number of subjects: 9838

Group type: EXPERIMENTAL
Intervention: Concomitant occurrence of diabetes and smoking
Number of subjects: 9838

Group type: EXPERIMENTAL
Intervention: Simultaneous presence of older age and diabetes or smoking
Number of subjects: 9838
Study: 36137526

Group type: EXPERIMENTAL
Intervention: MicroShunt implantation with adjunctive use of mitomycin C (0.2-0.4 mg/mL applied for 2-3 min)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: MicroShunt implantation
Number of subjects: 61
Study: 36137583

Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-marijuana smokers)
Number of subjects: 0
Study: 36137639

Group type: EXPERIMENTAL
Intervention: ChemoFit intervention (home-based physical activity and exercise intervention involving cardiovascular and strength exercise using resistance bands and pedometers)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ChemoFit intervention
Number of subjects: 22
Study: 36137658

Group type: EXPERIMENTAL
Intervention: Multi-inflow time arterial spin-labeling
Number of subjects: 44
Study: 36137674

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 557
Study: 36137711

Group type: EXPERIMENTAL
Intervention: VS-guided ablation using a contact force-sensing catheter
Number of subjects: 283
Study: 36137735

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 4362

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 4362

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 4362
Study: 36137752

Group type: EXPERIMENTAL
Intervention: MICs infusion before kidney transplantation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MICs infusion (highest dose) 7 days before surgery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MICs infusion (highest dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MICs infusion
Number of subjects: 10
Study: 36138060

Group type: EXPERIMENTAL
Intervention: First visit behaviors
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Second visit behaviors
Number of subjects: 277

Group type: COMPARATOR
Intervention: COVID-19 risk perception
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Strong behavioral changes at first visit
Number of subjects: 277
Study: 36138138

Group type: EXPERIMENTAL
Intervention: Biomass fuel use
Number of subjects: 497

Group type: COMPARATOR
Intervention: Liquified petroleum gas (LPG)
Number of subjects: 497
Study: 36138152

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Tisagenlecleucel (tisa-cel)
Number of subjects: 418
Study: 36138330

Group type: EXPERIMENTAL
Intervention: FACIT-F scale
Number of subjects: 0
Study: 36138362

Group type: EXPERIMENTAL
Intervention: Chemotherapy with immunotherapy
Number of subjects: 770

Group type: COMPARATOR
Intervention: Chemotherapy without immunotherapy
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: LELC
Number of subjects: 770

Group type: COMPARATOR
Intervention: LELC vs. NPC
Number of subjects: 770
Study: 36138368

Group type: EXPERIMENTAL
Intervention: Breastfeeding for at least 6 months
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Breastfeeding exclusively for at least 6 months
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Not smoking in the month prior to delivery
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Having a Master's degree or higher
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Having a planned pregnancy
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Less anxiety measured during pregnancy
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Hispanic women
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black women
Number of subjects: 5249
Study: 36138689

Group type: EXPERIMENTAL
Intervention: Standardised intervention (details not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 0
Study: 36139154

Group type: EXPERIMENTAL
Intervention: PLK-cleaved LAP-TGF-β
Number of subjects: 34
Study: 36139632

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 43